Last updated: March 20, 2024
Sponsor: The Hospital for Sick Children
Overall Status: Completed
Phase
N/A
Condition
Idiopathic Inflammatory Myopathies
Lupus
Myositis
Treatment
ubiquinol
gel capsule
creatine monohydrate
Clinical Study ID
NCT04286178
1000062314
HC6-24-c228771
Ages 7-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Ages 7 to 18 years
- Diagnosis of juvenile idiopathic inflammatory myopathy (JIIM) according to the 2017European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)criteria: ≥90% probability, age of onset <18 years
- Subjects on a stable course of medication (unlikely to change over study treatmentperiod as determined by treating physician)
- Minimum height of 132.5cm (required to fit on the cycle ergometer)
Exclusion
Exclusion Criteria:
- Subjects with newly diagnosed JIIM within the previous 6 months
- Subjects unable to cooperate with study procedures, or too weak to participate in theexercise testing
- Subjects with impaired kidney function as determined from pre-baseline visit screeninglab values (eGFR <90 ml/min/1.73m^2)
- Subjects currently taking anti-hypertensive drugs or blood thinners
- Subjects who are currently pregnant or planning to become pregnant within the studyperiod
Study Design
Total Participants: 15
Treatment Group(s): 5
Primary Treatment: ubiquinol
Phase:
Study Start date:
April 06, 2021
Estimated Completion Date:
March 05, 2024
Connect with a study center
The Hospital for Sick Children
Toronto, Ontario M5G 1X8
CanadaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.